Prednisolone with or without azathioprine is widely used in treating chronic active hepatitis and prospective controlled trials have shown benefit in HBsAg negative patients, particularly those with the 'autoimmune' type of disease. 13 Further analysis of one of these trials4 suggested that HBsAg positive patients failed to respond to conventional doses of prednisolone. More recent evidence indicates that such therapy may potentiate viral replication5 6 and have a deleterious effect. 7 There are two phases of chronic HBV infection. In the early years the virus can be detected readily in the serum by electron microscopy8 and by disappears from the blood, HBsAg concentrations fall, and anti-HBe develops.10
The aim of this study was to determine whether starting or stopping prednisolone/azathioprine in patients with chronic HBeAg or anti-HBe positive HBV induced liver disease, altered the markers of viral replication (HBsAg, HBeAg/anti-HBe and DNA polymerase activity) and biochemical tests of liver function, and to identify those who might benefit from this therapy. 
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